Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model

Zhou, Xian; Zhang, Shijie; Yu, Fan; Zhao, Gan; Geng, Shuang; Yu, Wencong; Wang, Xuanyi; Wang, Bin

doi:10.1080/21645515.2019.1616504

Cited by 3 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To find potential drugs for DFUs treatment, drug-gene and gene-gene drug-gene network maps were created. In one study ( 34 ), diabetic rats given the immunosuppressant CYCLOSPORINE showed a proportional decrease in serum glucose levels. In diabetic mice, low-dose preconditioning with SIMVASTATIN boosted angiogenesis, decreased inflammation, and enhanced wound healing ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

Characterization of the microenvironment of diabetic foot ulcers and potential drug identification based on scRNA-seq

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundDiabetes foot ulcers (DFUs) are a type of foot infection, ulcer, and/or deep tissue destruction caused by neuropathy and vascular disease in the distal extremities of diabetic patients. Its pathogenesis and its microenvironment are not entirely understood.MethodsInitially, the GSE165816 data set from the GEO database was utilized for single cell analysis to reveal the microenvironment and functional status of DFUs. The GSE199939 RNA-seq data set was utilized for external validation. On the basis of the logistic regression machine learning algorithm (OCLR), pseudo time series analysis, dryness index analysis, and drug target gene analysis were then performed. By constructing drug-gene and gene-gene networks, we can locate the most recent DFUs treatments. Finally, immunofluorescence technology was used to detect the cell-related markers of the DFUs microenvironment, and qPCR was used to detect the expression of drug targets in DFUs.ResultsFirstly, we used the Cell Maker database to obtain information about human cells and related gene markers, and manually reviewed a total of 45 kinds of cells and maker information that may appear in the DFUs microenvironment, which were divided into 17 cell clusters after annotation. Subsequently, we counted the proportions of DM and DFUs in different types of cells, and the results showed that the proportions of macrophages, white blood cells, and monocytes were higher in patients with DFUs, while the proportions of pluripotent stem cells and stromal cells were higher in patients with DM. The Pseudo-time series analysis of cells in DFUs showed that the differentiation pathways of immune cells, mesenchymal cells and stem cells were similar in the three states, while the other cells were distributed in different stages. At the level of a single cell, the scores of both multipotential stem cells and hematopoietic stem cells were significantly lower in DFU healing and non-healing than in DM. Additionally, the highly expressed genes in DFU were chosen as drug targets. We identified seven potential target genes and discovered twenty drugs with high significance. Finally, the colocalization relationship between CD19, ITGAM, and HLA-DR expression in monocytes and macrophages of DFU skin tissue and healthy subjects was analyzed by laser confocal microscopy with the immunofluorescence triple labeling method. The results showed that the expressions of CD19, ITGAM, and HLA-DR in the skin of DFUs were significantly higher than those in the skin of healthy subjects, and the co-localization relationship was significant in DFUs.ConclusionThis study can serve as a resource for the treatment of DFUs.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of the microenvironment of diabetic foot ulcers and potential drug identification based on scRNA-seq

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…As an antigen-specific monotherapy, ADi-100 is highly e cacious in reversing elevated hyperglycemia to prevent diabetes, where a promising feature of immune tolerance is the increased apoptosis-inducing BAX content (Alleva et al ,2020). It has been shown that the formulated autoantigenic islet peptides (GAD65206-220, GAD65536-550, Insulin B9-23, and C17-A1) used as a tolerogenic vaccine prevented T1D from developing in prediabetic NOD mice (Zhou et al, 2020).…”

Section: Prevent Of Type 1 Of Diabetes By Gene Therapymentioning

confidence: 99%

The Role of Gene Therapy in the Treatments of Type 1 Diabetes Mellitus: a review

Smail

2020

BIOMEDNATPROCH

View full text Add to dashboard Cite

The main aims of this review were to understand the roles of gene therapy in the treatment and prevention of type 1 diabetes mellitus and I will discuss a brief history, approaches, vector types with the future of diabetes following clinical use. Type 1 diabetes mellitus is a metabolic condition that is identified by insufficient insulin development due to pancreatic damage to beta cells. Control, long life, and diagnosis of these metabolic disorders have become vital sources for many scientists and researchers. After 2000, the latest approaches to molecular medicine were introduced as one of the possible therapeutic options for diabetes type 1 diagnosis. Many genes have been reported as a clinical trial so that damaged genes can be treated and three main approaches shown about 50 years ago are islet transplantation, β cell regeneration, and insulin gene therapy to cure and prevent diabetes type. Treating diabetes through gene therapy can promise children and adolescents, but more clinical applications are needed to recognize it as a permanent route.

show abstract

Diabetes mellitus and diabetic foot ulcer: Etiology, biochemical and molecular based treatment strategies via gene and nanotherapy

Mariadoss

Sivakumar

Lee

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model

Cited by 3 publications

References 51 publications

Characterization of the microenvironment of diabetic foot ulcers and potential drug identification based on scRNA-seq

Characterization of the microenvironment of diabetic foot ulcers and potential drug identification based on scRNA-seq

The Role of Gene Therapy in the Treatments of Type 1 Diabetes Mellitus: a review

Diabetes mellitus and diabetic foot ulcer: Etiology, biochemical and molecular based treatment strategies via gene and nanotherapy

Contact Info

Product

Resources

About